Objectives: Antipsychotics are used to manage the behavioral and psychological symptoms of dementia (BPSD), despite their association with greater risks for mortality and cerebrovascular events. Previous studies in Japan have estimated the prevalence of antipsychotics among older adults who took antidementia drugs. Using long-term care (LTC) data, we aimed to obtain more accurate estimates of the prevalence of antipsychotics and to determine factors related to their use in older adults with dementia.
Methods: Medical and LTC claims data and LTC certification data between April 2012 and September 2013 were obtained from a middle-sized suburban city. The 1-year prevalence of antipsychotic use was estimated among individuals with probable dementia aged greater than or equal to 75 years who were prescribed antidementia drugs and/or had dementia based on LTC needs certification data.
Results: Of 25 919 participants, 4865 had probable dementia and 1506 were prescribed antidementia drugs. The prevalence of antipsychotics among participants with probable dementia was 10.7%, which was lower than that in those who were prescribed antidementia drugs (16.4%). Among participants with probable dementia with LTC certification data available (N = 4419), lower cognitive function (vs mild; adjusted odds ratio 2.16, 95% confidence interval 1.63-2.86), antidementia drug use (2.27, 1.84-2.81), and institutional LTC services use (2.34, 1.85-2.97) were associated with greater odds of antipsychotic use, whereas older age (greater than or equal to 92 years) was associated with lower odds (vs less than 77 years; 0.42, 0.27-0.65).
Conclusions: These findings may be useful for estimating the burden of BPSD and for taking measures to reduce inappropriate antipsychotic prescription.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590349 | PMC |
http://dx.doi.org/10.1002/gps.5041 | DOI Listing |
J Alzheimers Dis
October 2024
Ace Alzheimer Center Barcelona-Universitat Internacional de Catalunya, Barcelona, Spain.
Front Psychiatry
September 2024
Department of Neuropsychiatry, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Takatsuki, Osaka, Japan.
Alzheimers Dement
November 2024
Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, Western Australia, Australia.
Introduction: We investigated longitudinal associations between self-reported exercise and Alzheimer's disease (AD)-related biomarkers in individuals with autosomal dominant AD (ADAD) mutations.
Methods: Participants were 308 ADAD mutation carriers aged 39.7 ± 10.
J Am Geriatr Soc
September 2024
Center for Gerontology and Healthcare Research, Brown University School of Public Health, Providence, Rhode Island, USA.
Background: Antipsychotic and other psychotropic medication use is prevalent among community-dwelling older adults with dementia despite the potential for adverse effects. Two Centers for Medicare & Medicaid Services (CMS) initiatives, the National Partnership to Improve Dementia Care ("the Partnership") and the Five Star Quality Rating System for antipsychotic use reporting, have been successful in reducing antipsychotic use in nursing home residents. We assessed if these initiatives had a spillover effect in antipsychotic and other psychotropic medication use among community dwellers with dementia due to potential overlap in prescribers across settings.
View Article and Find Full Text PDFJ Am Med Dir Assoc
November 2024
The University of Sydney, School of Pharmacy, Faculty of Medicine and Health, Sydney, New South Wales, Australia; Kolling Institute, The University of Sydney Faculty of Medicine and Health, Northern Clinical School and Northern Sydney Local Health District, Royal North Shore Hospital, St Leonards, New South Wales, Australia; Pharmaceutical Policy Node, Charles Perkins Centre, The University of Sydney, New South Wales, Australia. Electronic address:
Objectives: To estimate the national prevalence of antidementia and psychotropic medication use, and sociodemographic factors associated with their use, in Australians living with dementia.
Design: Retrospective cross-sectional study.
Setting And Participants: Nationwide data linkage study using 2021 Census and Pharmaceutical Benefits Scheme (PBS) data.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!